Akari Therapeutics (AKTX) AI Stock Analysis

• Market Cap: $38.29M
• Dividend Yield: N/A
• Average Volume (3M): 33.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 28,876,492
• 10 Day Avg. Volume: 43,493
• 30 Day Avg. Volume: 33,278
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 10.00T>
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Akari Therapeutics' stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company's speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.

Akari Therapeutics Business Overview & Revenue Model

Company Description

Akari Therapeutics Plc is a biopharmaceutical company focused on developing innovative treatments for rare and orphan diseases, particularly those involving severe inflammatory and allergic conditions. The company operates in the biotechnology sector, with its core products centered around inhibitors of the complement and leukotriene systems, which play a crucial role in the body's immune response.

How the Company Makes Money

Akari Therapeutics primarily makes money through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships, licensing agreements, and potential sales of its therapeutic products upon receiving regulatory approval. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies that have the resources to bring Akari's products to market. Additionally, Akari may receive research and development funding from grants or governmental and non-governmental organizations, supporting its ongoing drug development efforts.

Akari Therapeutics Financial Statement Overview

Summary

Akari Therapeutics is experiencing significant financial instability, with consistent losses, negative equity, and reliance on external financing. These challenges are typical for early-stage biotech firms but pose high risks for investors.

Income Statement

Akari Therapeutics shows a consistent lack of revenue generation over the years, which is typical for early-stage biotechnology companies focusing on R&D. The company has faced increasing net losses, with the most recent TTM losses larger than previous annual figures. This indicates significant challenges in controlling operational costs, impacting margins negatively.

Balance Sheet

The balance sheet reveals a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The company has introduced debt, increasing financial risk, especially with negative equity, suggesting potential solvency issues. The declining equity ratio and increasing liabilities highlight financial instability.

Cash Flow

The cash flow statement indicates persistent negative operating cash flow, pointing to operational challenges in generating cash. The company relies heavily on financing activities to fund its operations, as free cash flow remains negative. The lack of revenue generation further compounds the weak cash flow situation.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
―	―	―	―	-19.20K
	EBIT
-16.81M	-23.09M	-17.21M	-17.98M	-24.87M
	EBITDA
-16.80M	-23.08M	-17.21M	-20.44M	-24.73M
	Net Income Common Stockholders
-10.01M	-6.97M	-17.61M	-17.60M	-21.76M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.85M	13.25M	9.36M	14.06M	5.73M
	Total Assets
4.36M	13.83M	11.65M	17.59M	10.31M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-3.85M	-13.25M	-9.36M	-14.06M	-5.73M
	Total Liabilities
4.58M	12.04M	6.09M	5.22M	6.47M
	Stockholders Equity
-229.00K	1.79M	5.55M	12.38M	3.84M
Cash Flow		Free Cash Flow
-16.43M	-21.50M	-18.85M	-16.95M	-12.26M
	Operating Cash Flow
-16.43M	-21.50M	-18.85M	-16.95M	-12.26M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
7.02M	25.29M	14.29M	25.07M	11.99M

Akari Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.15, and below the 200-day MA of 2.05, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 61.33 is Neutral, neither overbought nor oversold. The STOCH value of 67.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AKTX.

Akari Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
LTRN	45 Neutral	$39.04M	―	-66.93%	―	―	-31.16%
LVTX	45 Neutral	$28.67M	―	-63.40%	―	77.01%	41.46%
AKTX	44 Neutral	$38.29M	―	291.66%	―	―	―
STTK	39 Underperform	$47.37M	―	-67.23%	―	245.26%	27.54%
XFOR	39 Underperform	$24.95M	―	-102.26%	―	―	69.37%

Akari Therapeutics Corporate Events

Akari Therapeutics Appoints New CEO Abizer Gaslightwala

On March 14, 2025, Akari Therapeutics announced the appointment of Mr. Abizer Gaslightwala as the new President and Chief Executive Officer, effective April 21, 2025. Mr. Gaslightwala, who has a robust background in the pharmaceutical industry with leadership roles at Jazz Pharmaceuticals, Amgen, and Pfizer, will replace Dr. Samir R. Patel, who will step down on April 14, 2025, but remain on the board. This leadership change is expected to bring strategic insights and strengthen Akari’s market position in the biopharmaceutical sector.